Feature | December 07, 2012

Tryton Completes Patient Enrollment in Pivotal FDA Side Branch Stent Trial

Study Is the first and largest randomized multi-center bifurcation trial

Tryton Side Branch Stent TRYTON Pivotal FDA IDE trial

December 7, 2012 — Tryton Medical Inc. announced the completion of enrollment in the TRYTON Pivotal U.S. Food and Drug Administration (FDA) IDE trial evaluating the Tryton Side Branch Stent.

The landmark TRYTON pivotal study is an international randomized trial that compares a Tryton stent in the side branch vs. conventional provisional stenting (balloon angioplasty) in the side branch, with both arms of the trial utilizing a standard drug eluting stent in the main vessel. The study, which is the first and only randomized IDE pivotal clinical trial to evaluate a dedicated bifurcation stent, has enrolled 704 patients at 67 centers in North America, Europe and Israel. The primary endpoint of the study is target vessel failure at nine months. A secondary endpoint is percent diameter stenosis at nine months in the side branch vessel.

Martin B. Leon, M.D., F.A.C.C., professor of Medicine and director of the Center for Interventional Vascular Therapy at Columbia University Medical Center, and founder and chairman emeritus of the Cardiovascular Research Foundation, serves as principal investigator of the study.

“Completion of patient recruitment is a major milestone for the TRYTON IDE Pivotal Trial, which is truly a landmark study. In addition to being the first powered randomized controlled trial evaluating a dedicated side branch stent, it is the largest coronary bifurcation study ever attempted and the first one to have core angiographic (3-D and planar) and IVUS sub-studies. The results of the TRYTON study will directly guide the treatment of patients with complex bifurcation disease,” said Leon. “Our current inability to treat these lesions with ‘work horse’ drug eluting stents, represents an important unmet clinical need which confronts interventional cardiologists. From my travels to Europe and Israel, I have been impressed with how easily the Tryton Stent is incorporated into routine practice. We look forward to results from this trial.”

“Tryton Medical’s differentiated technology addresses the challenges of bifurcated lesions, which affect nearly a third of patients undergoing a PCI procedure. Data from more than 1,000 registry patients in Europe treated with the Tryton stent are already challenging provisional stenting, with compelling results of target lesion revascularization of four percent and thrombosis of 0.5 percent at one year," said Shawn P. McCarthy, president and CEO of Tryton Medical. “We are looking to corroborate this positive registry data in the TRYTON Medical randomized controlled study. With more than 6,000 implants to date, we are leveraging our impressive data to further expand globally. We are on track to be the first and only approved stent for coronary bifurcations in the U.S.”

Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of the stented vessel following implantation. In patients undergoing PCI-stenting, approximately one-third have a bifurcation lesion. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions.

For more information please visit www.trytonmedical.com

Related Content

Svelte Medical Systems, CE Mark, Direct RX, Direct sirolimus-eluting coronary stent rapid exchange system, drug-eluting stent, DES
News | Stents| October 28, 2016
Svelte Medical Systems Inc. announced this week it received CE Mark certification of the Direct Sirolimus-Eluting...
RFID inventory control in the cath lab, inventory management, cardinal

An example of RFID cabinets in a cath lab. As items are pulled from the cabinet, the inventory control system automatically determines what items were take out and adds them to the patient case. The system can also help locate recalled or expired items, and automatically track on-hand inventory to avoid manual counts.

Feature | Inventory Management| October 28, 2016 | Jean-Claude Saghbini
The healthcare industry’s transition to value-based care leaves no room for waste, and yet we know that inefficiency
Sponsored Content | Videos | Sudden Cardiac Arrest| October 28, 2016
It is critical to educate patients who are at risk of sudden cardiac arrest (SCA), so Rahul Doshi, M.D., director of
tryton side branch stent, bifurcation stenting, Cardinal Health
News | Stents Bifurcation| October 28, 2016
October 28, 2016 – Tryton Medical Inc., a primary developer of stents to treat coronary bifurcation lesions, and Card
Sponsored Content | Videos | Inventory Management| October 28, 2016
With quality of care and cost efficiency at the top of your mind, there is no room in your hospital for waste from hi
Aggrastat Bolus Vial, IV antiplatelet agent
Technology | Antiplatelet and Anticoagulation Therapies| October 28, 2016
October 28, 2016 — Medicure Inc. recently received U.S.
Acutus Medical, AcQMap High Resolution Imaging and Mapping System, atrial fibrillation, UNCOVER-AF trial, first procedure
News | EP Mapping and Imaging Systems| October 27, 2016
Acutus Medical announced the completion of the first patient procedure in the “Utilizing Novel Dipole Density...
PCI, operator volume, China study, JACC, outcomes
News | Cath Lab| October 27, 2016
Volume matters when it comes to who does certain procedures to removing heart-attack causing blockages from arteries,...
Corindus, Corpath, robotic navigation, Robotic PCI, CorPath GRX
Technology | October 27, 2016
October 27, 2016 — Corindus Vascular Robotics Inc. announced it received 510(k) clearance from the U.S.
Overlay Init